Artivion, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission on August 7, 2026, reporting total revenues of $125.8 million and a net loss of $13.5 million for the second quarter.

Key Highlights

  • Total Q2 2026 revenues: $125,757 thousand, up from $112,972 thousand in Q2 2025.
  • Net loss for Q2 2026: $13,510 thousand, compared to net income of $1,345 thousand in Q2 2025.
  • Basic and diluted loss per share: $(0.28) for Q2 2026, versus $0.03 income per share in Q2 2025.
  • Endospan acquisition: The company paid $116,661 thousand, net of cash acquired, for the acquisition of Endospan during the six months ended June 30, 2026.
  • Total assets: $1,071,934 thousand as of June 30, 2026, up from $884,796 thousand at December 31, 2025.
  • Long-term debt, net: $363,423 thousand as of June 30, 2026, compared to $215,114 thousand at December 31, 2025.
  • Shares outstanding: 48,756,221 shares of common stock as of July 31, 2026.

Artivion's Q2 2026 Financial Results: Revenue Growth, Wider Losses, and Endospan Acquisition

According to the filing, Artivion, Inc. (New York Stock Exchange: AORT) reported total revenues of $125,757 thousand for the three months ended June 30, 2026, consisting of $99,905 thousand from products and $25,852 thousand from preservation services. This compares to total revenues of $112,972 thousand in the same period of 2025. For the six months ended June 30, 2026, the company reported total revenues of $242,094 thousand, up from $211,950 thousand in the first half of 2025.

The company disclosed a net loss of $13,510 thousand for Q2 2026, compared to net income of $1,345 thousand in Q2 2025. The filing attributed the swing in part to higher general, administrative, and marketing expenses, which rose to $79,826 thousand in Q2 2026 from $57,665 thousand in Q2 2025. Total operating expenses for the quarter reached $88,881 thousand, resulting in an operating loss of $8,364 thousand, versus operating income of $8,384 thousand a year earlier. Research and development expenses were $9,055 thousand in Q2 2026, up from $7,063 thousand in Q2 2025.

On the balance sheet, the filing reported goodwill of $349,862 thousand as of June 30, 2026, a significant increase from $254,091 thousand at December 31, 2025, reflecting the acquisition of Endospan. The company disclosed that proceeds from issuance of long-term debt, net, were $148,875 thousand during the first half of 2026, funding in part the $116,661 thousand cash outlay for Endospan. Cash and cash equivalents stood at $77,316 thousand at June 30, 2026, compared to $64,908 thousand at December 31, 2025. Net cash used in operating activities was $112 thousand for the six months ended June 30, 2026.

What Was Disclosed

Artivion filed its quarterly report covering the period ended June 30, 2026, disclosing revenue growth year-over-year, a net loss driven by higher operating expenses, the completed acquisition of Endospan, increased long-term debt, and 48,756,221 shares of common stock outstanding as of July 31, 2026.